Bisacodyl Enema Administration and Safety

Indications and Contraindications

Bisacodyl enemas are indicated as first-line therapy when digital rectal examination identifies a full rectum or fecal impaction, according to the American Society of Clinical Oncology 1, 2, 3
They are contraindicated in patients with neutropenia or thrombocytopenia, paralytic ileus or intestinal obstruction, recent colorectal or gynecological surgery, recent anal or rectal trauma, severe colitis, inflammation, or infection of the abdomen, toxic megacolon, undiagnosed abdominal pain, and recent radiotherapy to the pelvic area 1, 2, 3, 4

The docusate sodium component (if present in combination formulations) takes 5-20 minutes to soften stool by aiding water penetration, as recommended by the American Society of Clinical Oncology 1
For optimal effect, bisacodyl enemas should be retained for at least a few minutes to allow the medication to stimulate rectal motility, according to the American Society of Clinical Oncology 1
Bisacodyl enemas are preferred over oral laxatives when rapid bowel evacuation is needed, as enemas work more quickly than oral agents, as stated by the American Society of Clinical Oncology 2

Abdominal discomfort including cramps and abdominal pain is common with bisacodyl enemas, as reported by the American Society of Clinical Oncology 1, 4
Short-lasting diarrhea may occur, according to the American Society of Clinical Oncology 1
Anal or rectal burning and pain can develop, as stated by the American Society of Clinical Oncology 1

If no bowel movement occurs within 1 hour, reassessment for impaction or obstruction is warranted, as recommended by the National Comprehensive Cancer Network 5, 6
The enema should be administered by an experienced healthcare professional when dealing with severe impaction or in high-risk patients, according to the American Society of Clinical Oncology 2